Germany research report
Read a source-linked Germany psilocybin research report with live indexed trial statistics, EPIsoDE evidence, research sites and dated access context.
Free access · No subscription for research tools or data exports
Germany: research and access context
Editorial sources checked . Registry facts refresh separately; the latest indexed registry check is Nov 19, 2026 02:23 UTC. This report covers psilocybin and psilocin, not the entire psychedelic sector.
Controlled substances
Psilocybin and psilocin are listed in Anlage I of the BtMG. This controlled status and any authorised research or exceptional-access pathway must be considered separately.
Confirmed cohort programme
The BfArM table lists psilocybin for treatment-resistant depression under the Central Institute of Mental Health, with confirmed notification dated 18 June 2026 and programme duration through 17 June 2027. A listed programme is not general marketing authorisation or a promise of eligibility.
Published German evidence
EPIsoDE is a published randomized report, not evidence inferred from registration. Its primary response comparison was not significant. Read the endpoint, safety findings and limitations before interpreting exploratory symptom changes.
Mannheim and Berlin
ZI Mannheim describes research with Charité and MIND Foundation, and the exceptional-access programme at ZI and OVID Berlin. These organisations have different research, education and treatment roles; inclusion is not an endorsement.
Access, payment and evidence are separate questions
The BfArM procedure and AMHV concern cohort programmes, not individual named-patient applications. Current entry criteria and capacity must be checked with the responsible programme. A registry recruitment flag does not establish personal eligibility.
The G-BA explanation of AMNOG describes added-benefit assessment and its role in reimbursement pricing. It does not establish a psilocybin reimbursement decision. This report does not assert routine insurance coverage, a treatment price, or a regulatory approval forecast.
Explore registry geography and organisations
1 trials match this view; 2 reported facilities; 2 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 144 across 1 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major DepressionTreatment-resistant Depression | Central Institute of Mental Health, Mannheim PHASE2 | Completed Registry updated 2025-01-20 | 144 ACTUAL | 2021-06-10 2024-02-27 2024-12-11 | Evidence-guide report · Mertens et al. · EPISODE · 2026 |
Reported research facilities
Central Institute of Mental Health (CIMH)Mannheim, Germany · Coordinates available · Selected-country site
Charité Berlin, Campus Mitte, Department of Psychiatry and PsychotherapyBerlin, Germany · Coordinates available · Selected-country site
This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.